Abenava Medipharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.75 M
- Company Age 13 Year, 30 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
- Revenue Growth -1.74%
- Profit Growth 30.94%
- Ebitda 97.83%
- Net Worth 21.82%
- Total Assets 10.12%
About Abenava Medipharma
Abenava Medipharma Private Limited (AMPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2012 and has a history of 13 years. Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M.
The company currently has active open charges totaling ₹3.00 M.
Navendra Singh and Renu Rathi serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2012PTC048369
-
Company No.
048369
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Jan 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Abenava Medipharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navendra Singh
|
Director | 16-Jan-2012 | Current |
|
Renu Rathi
|
Director | 16-Jan-2012 | Current |
Financial Performance of Abenava Medipharma.
Abenava Medipharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.74% decrease. The company also saw a substantial improvement in profitability, with a 30.94% increase in profit. The company's net worth Soared by an impressive increase of 21.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abenava Medipharma?
In 2017, Abenava Medipharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Javitri Devi Sheetgrah Private LimitedNavendra Singh and Renu Rathi are mutual person
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jun 2015 | Canara Bank | ₹3.00 M | Open |
How Many Employees Work at Abenava Medipharma?
Unlock and access historical data on people associated with Abenava Medipharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abenava Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abenava Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.